8-K: Oncocyte Reports Progress in Transplant Testing Commercialization and Secures $10.2 Million in Private Placement

Oncocyte is making significant strides in commercializing its transplant testing technology, securing new research customers and advancing its clinical kitted test development, while also raising $10.2 million through a private placement.

Summary

• Oncocyte is focused on commercializing its organ transplant testing technology, particularly through a kitted test for donor-derived cell-free DNA (dd-cfDNA).
• The company has signed agreements with several leading transplant university hospitals in the U.S., Germany, Switzerland, Austria, and the U.K. for its research-use-only GraftAssure assay.
• German customers represent about 9% of the country's annual organ transplant volumes, while U.S. customers represent about 2% of the U.S. transplant volumes.
• Oncocyte is on track to have more than 20 transplant centers using GraftAssure by the end of 2025, with each center potentially generating $200,000 to $2 million in annual revenue.
• The company has submitted a plan for an in-vitro diagnostic (IVD) version of the dd-cfDNA kitted test to the FDA and has scheduled a meeting for early December.
• Oncocyte's Q3 2024 revenue was $115,000, primarily from pharma services, with a gross profit of $50,000.
• Operating expenses were $13.6 million, including non-cash items, and the net loss from continuing operations was $13.5 million, or $0.98 per share.
• The company completed a private placement on October 2, 2024, raising gross proceeds of $10.2 million, and net proceeds of approximately $9.4 million after fees.
• Oncocyte's cash balance at the end of Q3 2024 was approximately $5.1 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in commercialization and regulatory pathways, the significant net loss and cash burn are concerning. The successful capital raise is a positive, but the overall sentiment is neutral to slightly negative due to the financial challenges.

Positives

• The company is successfully signing new research customers at well-respected hospitals and universities.
• The international response to GraftAssure is exceeding expectations.
• Oncocyte is making inroads into the much larger U.S. market.
• The company is on track to meet its commitment to have more than 20 transplant centers running GraftAssure tests by the end of 2025.
• The FDA pre-submission process for the clinical kitted test is progressing as planned.
• The company has secured $10.2 million in gross proceeds through a private placement.
• The company's research and development efforts are supported by multiple publications demonstrating the clinical value of dd-cfDNA.

Negatives

• The company is currently pre-revenue in terms of its transplant tests, with Q3 2024 revenue of only $115,000.
• The company reported a significant net loss from continuing operations of $13.5 million in Q3 2024.
• The company's cash balance decreased by $5.9 million sequentially to $5.1 million at the end of Q3 2024.
• Operating expenses are high at $13.6 million, including a $7.1 million non-cash expense from the change in fair value of contingent consideration.

Risks

• The company is dependent on regulatory approvals for its clinical-use products.
• The company needs to secure reimbursement from Medicare and other payors for its tests.
• The company is currently operating at a loss and requires additional capital to fund operations and growth.
• The company faces competition in the diagnostics market.
• The company's success depends on the adoption of its tests by transplant centers.

Future Outlook

Oncocyte expects to continue to expand its customer base for GraftAssure, obtain regulatory clearance for its VitaGraft+ test, and generate meaningful revenue from its transplant testing products. The company also anticipates potential claims expansion for dd-cfDNA monitoring.

Management Comments

• We are pleased to report that we are making considerable progress on two fronts that help de-risk our path to meaningful revenue.
• We believe each new customer represents a key step toward capturing an estimated $1 billion global total addressable market for our transplant rejection testing technology.
• We are on track to meet the commitment that we made to investors in August to have more than 20 transplant centers running GraftAssure tests through the end of 2025.
• We feel confident in our ability to continue to execute on critical milestones and access capital to fund operations and growth.

Industry Context

The announcement highlights Oncocyte's efforts to disrupt the transplant diagnostics market by offering a faster, more affordable, and decentralized testing solution using digital PCR technology. This contrasts with traditional methods that rely on Next-Generation Sequencing (NGS) and centralized labs. The company is leveraging its scientific expertise in dd-cfDNA to gain a competitive edge.

Comparison to Industry Standards

• The company's focus on digital PCR technology for dd-cfDNA testing is a differentiator compared to companies using NGS, such as CareDx and Natera, which are also active in the transplant monitoring space.
• CareDx, for example, offers AlloSure, a donor-derived cell-free DNA test for transplant rejection, and has a larger market presence and revenue base than Oncocyte at this stage.
• Natera's Prospera test is another competitor in the transplant space, utilizing NGS technology.
• Oncocyte's strategy of starting with research-use-only products and then transitioning to clinical-use products is a common approach in the diagnostics industry, similar to how other companies have launched new tests.
• The company's goal of enabling local labs to perform testing aligns with a trend towards decentralized diagnostics, which can improve turnaround times and reduce costs.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and the recent private placement.
• Employees will be impacted by the company's growth and commercialization efforts.
• Customers (transplant centers) will benefit from the company's testing technology.
• Suppliers will be impacted by the company's demand for its products.
• Creditors will be impacted by the company's financial performance and ability to repay debts.

Next Steps

• Oncocyte will continue to expand its customer base for GraftAssure.
• The company will continue to engage with the FDA regarding the IVD version of its dd-cfDNA kitted test.
• Oncocyte will pursue regulatory clearance for its VitaGraft+ test.
• The company will work to secure reimbursement from Medicare and other payors.
• Oncocyte will continue to advance the science of dd-cfDNA and demonstrate its clinical value.

Key Dates

Keywords

transplant, dd-cfDNA, GraftAssure, VitaGraft, diagnostics, FDA, IVD, digital PCR, rejection, biomarker, oncology, DetermaIO, private placement